Immunomodulators, including TLR7 agonists combined with iNOS inhibitors, modulate NO levels to enhance cytotoxic T-cell and macrophage activity, boosting immune-mediated tumor cell killing (PeÑarando et al., 2019). The gene discussed is NOS2; the disease is neoplasm.